Scarica l'app Stockscreener
9.22
2.79%
0.25
Dopo l'orario di chiusura:
9.22
Precedente Chiudi:
$8.97
Aprire:
$8.97
Volume 24 ore:
578.76K
Relative Volume:
0.91
Capitalizzazione di mercato:
$326.51M
Reddito:
$127.70M
Utile/perdita netta:
$-108.14M
Rapporto P/E:
-11.24
EPS:
-0.82
Flusso di cassa netto:
$-117.52M
1 W Prestazione:
+7.46%
1M Prestazione:
-7.98%
6M Prestazione:
-20.93%
1 anno Prestazione:
-10.83%
Intervallo 1D:
$8.70
$9.265
Intervallo di 1 settimana:
$8.41
$9.265
Portata 52W:
$8.41
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Nome
Iteos Therapeutics Inc
Settore
Industria
Telefono
857-204-4583
Indirizzo
321 ARSENAL STREET, WATERTOWN
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | SVB Leerink | Outperform |
| 2020-08-18 | Iniziato | Wedbush | Outperform |
Mostra tutto
Iteos Therapeutics Inc Borsa (ITOS) Ultime notizie
Iteos Therapeutics stock hits 52-week low at $8.49 By Investing.com - Investing.com South Africa
Iteos Therapeutics stock hits 52-week low at $8.49 - Investing.com
iTeos Therapeutics präsentiert auf dem Immunonkologie-Kongress der ESMO präklinische und translationale Daten sowie Daten aus der klinischen Phase-II-Studie A2A-005 zu Inupadenant bei NSCLC in der Zweitlinie - GlobeNewswire Inc.
iTeos Therapeutics to Highlight Inupadenant Preclinical, - GlobeNewswire
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress - StockTitan
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by nVerses Capital LLC - Defense World
Iteos Therapeutics stock hits 52-week low at $8.73 - Investing.com India
Iteos Therapeutics stock hits 52-week low at $8.73 By Investing.com - Investing.com Canada
Exchange Traded Concepts LLC Sells 6,414 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Looking At A Strong Finish To 2024 After Going From Fifth To First In TIGIT - Citeline
(ITOS) Proactive Strategies - Stock Traders Daily
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Position Decreased by AQR Capital Management LLC - MarketBeat
BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc - GuruFocus.com
ITeos Therapeutics Inc (ITOS) shows promising results - US Post News
Stock Performance Spotlight: ITeos Therapeutics Inc (ITOS) Ends the Day at 9.73, Down by -2.21 - The Dwinnex
ITOS Stock on the Rise: A Promising Investment - The InvestChronicle
Millennium Management LLC Decreases Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Millennium Management LLC Lowers Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update - Defense World
Squarepoint Ops LLC Sells 38,801 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
When (ITOS) Moves Investors should Listen - Stock Traders Daily
Did ITeos Therapeutics Inc (ITOS) perform well in the last session? - US Post News
Ratio Revelations: ITeos Therapeutics Inc (ITOS)’s Financial Metrics in the Spotlight - The Dwinnex
TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO - BioSpace
Dimensional Fund Advisors LP Raises Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
ITeos TherapeuticsAssessing Breakthrough Therapies To Treat Cancer - RTTNews
A new trading data show ITeos Therapeutics Inc (ITOS) is showing positive returns. - SETE News
American Century Companies Inc. Has $687,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
A closer look at ITeos Therapeutics Inc (ITOS)’s stock price trends - US Post News
Financial Metrics Exploration: Understanding ITeos Therapeutics Inc (ITOS) Through Ratios - The Dwinnex
How the (ITOS) price action is used to our Advantage - Stock Traders Daily
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeu - GuruFocus.com
156,894 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Bought by Clearline Capital LP - Defense World
Clearline Capital LP Invests $2.33 Million in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
There is no way ITeos Therapeutics Inc (ITOS) can keep these numbers up - SETE News
ESMO recap: Keeping TIGIT alive, Rybrevant & immunotherapy anniversary — a BioCentury podcast - BioCentury
ITeos Therapeutics Inc (ITOS) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Renaissance Technologies LLC Sells 157,700 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Rhumbline Advisers - Defense World
Renaissance Technologies LLC Has $8.30 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Analytical Lens: Exploring ITeos Therapeutics Inc (ITOS)’s Financial Story Through Ratios - The Dwinnex
The week in pharma: action, reaction and insight – week to September 2024 | Pharmaceutical | The Pharmaletter - The Pharma Letter
(ITOS) Investment Report - Stock Traders Daily
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + - Seeking Alpha
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Holdings Lifted by Victory Capital Management Inc. - Defense World
Bank of New York Mellon Corp Has $1.80 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
JPMorgan maintains Overweight rating on iTeos amid TIGIT data By Investing.com - Investing.com Canada
Wedbush Weighs in on iTeos Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:ITOS) - Defense World
FY2027 Earnings Estimate for iTeos Therapeutics, Inc. Issued By Wedbush (NASDAQ:ITOS) - MarketBeat
iTeos Therapeutics (NASDAQ:ITOS) Stock Rating Reaffirmed by HC Wainwright - Defense World
View from ESMO: iTeos data keep TIGIT alive, for now - BioCentury
Iteos Therapeutics Inc Azioni (ITOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):